Cornea breakthrough

Article

Harvested stem cells from patients' own eyes to rehabilitate damaged cornea in just ten days may prove to be a world-first breakthrough in restoring sight.

Harvested stem cells from patients' own eyes to rehabilitate damaged cornea in just ten days may prove to be a world-first breakthrough in restoring sight.

Medical researchers at the University of New South Wales (UNSW) used stem cells cultured on a common therapeutic contact lens which was then placed onto the damaged cornea for 10 days, during which the cells were able to re-colonise the damaged eye surface. The exciting new research is published in the journal Transplantation.The trial was conducted on just three patients; two with extensive corneal damage resulting from multiple surgeries to remove ocular melanomas, and one with the genetic eye condition aniridia.

"The procedure is totally simple and cheap," said lead author of the study, UNSW's Dr Nick Di Girolamo. "Unlike other techniques, it requires no foreign human or animal products, only the patient's own serum, and is completely non-invasive.

"There's no suturing, there is no major operation: all that's involved is harvesting a minute amount — less than a millimeter — of tissue from the ocular surface.

"If you're going to be treating these sorts of diseases in third world countries all you need is the surgeon and a lab for cell culture. You don't need any fancy equipment."

Because the procedure uses the patient's own stem cells harvested from their eye, it is ideal for sufferers of unilateral eye disease. However, it also works in patients who have had both eyes damaged, Dr Di Girolamo said.

"One of our patients had aniridia," explained Girolamo, "a congenital condition affecting both eyes. In that case, instead of taking the stem cells from the other cornea, we took them from another part of the eye altogether — the conjunctiva — which also harbours stem cells.

"The stem cells were able to change from the conjunctival phenotype to a corneal phenotype after we put them onto the cornea. That's the beauty of stem cells."

The therapeutic contact lens used in the trial was of a type commonly used worldwide after ocular surface surgery. However, of the several brands on the market, only one was suitable for growing the stem cells.

"We don't know why. It's probably to do with the components the manufacturers have used in that particular lens," Dr Di Girolamo said.

The researchers are hopeful the technique can be adapted for use in other parts of the eye, such as the retina. "If we can do this procedure in the eye, I don't see why it wouldn't work in other major organs such as the skin, which behaves in a very similar way to the cornea," concluded Dr Di Girolamo.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.